About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Secondary Prophylaxis Gastric Variceal Bleed | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT00888784

Secondary Prophylaxis Gastric Variceal Bleed

The investigators conducted a randomized, controlled trial (RCT) to study the efficacy of beta blockers versus endoscopic cyanoacrylate injection in the prevention of gastric variceal (GOV2 or IGV1) r...

Lead sponsor: Govind Ballabh Pant Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Govind Ballabh Pant Hospital

Age

10 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with GOV2 without esophageal varix or IGV1, who had bled from GV were included

Exclusion Criteria

•Presence of esophageal varix
•GOV2 with GOV1; contraindications to beta-blocker therapy and cyanoacrylate injection
•Prior injection of cyanoacrylate or sclerotherapy for GV or GV ligation, transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration, balloon-occluded endoscopic injection sclerotherapy of GV, shunt operation for prevention of rebleeding from GV
•Patients already on beta-blocker or nitrates
•Undetermined origin of bleeding from esophageal varix or gastric varix
•Hepatic encephalopathy grade III/IV
•Hepatorenal syndrome
•Hepatocellular carcinoma
•Presence of deep jaundice (serum bilirubin \> 10 mg/dl)
•Uremia
•Cerebrovascular accident
•Cardiorespiratory failure
•Pregnancy or patients not giving informed consent for endoscopic procedures

Related studies

Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)

NCT06345547 · Sarcopenia, Cirrhosis, and more

RECRUITINGPhase 1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

NCT07439939 · Liver Cirrhosis, Portal Hypertension

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

Online Prehabilitation for Patients Awaiting Liver Transplantation

NCT05899231 · Cirrhosis, Liver, Liver Transplant Surgery, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 28, 2009Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment64

Start dateAug 2006

Last updatedApr 28, 2009

Condition

Locations shown

G B Pant Hospital

New Delhi, National Capital Territory of Delhi

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 28, 2009Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions